HTAi's Presidents have played crucial roles in the growth and maturation of the Society, and each has made notable contributions to the promoting the development and use of HTA worldwide. Since its founding in 2003, HTAi has grown into a thriving network with close to 1300 members from around the world, and has become a major hub for global collaboration in HTA.
This page lists HTAi's Past Presidents in the order of their tenure, beginning with the most recent. The biographies below are circa the the first year of each President's tenure.
President - 2013-14 to 2014-15
Carole Longson is Director of the Centre for Health Technology Evaluation and an Executive Director at NICE. She has a doctorate in Pharmacology and spent 8 years in drug discovery at GlaxoSmithKline on the identification and development of novel pharmaceuticals across multiple therapeutic areas. She has undertaken many academic secondments including The Institute of Molecular Biology in Geneva and the University of California in Irvine, USA. She contributes to international policy forums, including the WHO advisory groups on Priority Medical Devices and Innovative Technologies and is President of Health Technology Assessment International. She also is a member of the scientific committee of the European Commission Innovative Medicines Initiative
Her research interests lie in the scientific methodologies of health technology assessment used in the context of health policy decision making.
Clifford Goodman, PhD
President 2011-12 to 2012-13
Clifford Goodman, PhD, is a Vice President at The Lewin Group, a health care policy and human services consulting firm located near Washington, DC. He has 30 years of experience in health care evaluation, including HTA, evidence-based health care, comparative effectiveness research, health economics, and studies pertaining to health care innovation, regulation, and payment. He directs studies and projects for an international range of government agencies; pharmaceutical, biotechnology, and medical device companies; health care provider institutions; and professional, industry, and patient advocacy groups. His recent work has involved studies in oncology, cardiovascular disease, diabetes, obesity, end-stage renal disease, pandemic influenza, follow-on biologics, wound care, health information technology, pharmacogenomics, diagnostic testing, and organ transplantation. He directed a Lewin team that provided technical support for the US Federal Coordinating Council for Comparative Effectiveness Research (including its Report to the President and The Congress, 2009). For the US Agency for Healthcare Research and Quality (AHRQ), he directed the Evidence-based Practice Centers Coordinating Center at The Lewin Group (2002-08). Dr. Goodman is chair (through May 2011) of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) for the US Centers for Medicare and Medicaid Services (CMS). He has testified to Congress on issues pertaining to Medicare coverage of health care technology. Earlier in his career, as a National Research Council Fellow and later as director of the Council on Health Care Technology, he managed and staffed a series of HTA projects at the Institute of Medicine, including the landmark study, Assessing Medical Technologies. Subsequently, he was a visiting researcher in Stockholm at the Swedish Council on Technology Assessment in Health Care (SBU). He is a founding board member of HTAi and is a Fellow of the American Institute for Medical and Biological Engineering. He serves on the editorial boards of the International Journal of Technology Assessment in Health Care and the American Journal of Managed Care. He did his undergraduate work at Cornell University, received a master's degree from the Georgia Institute of Technology, and earned his doctorate from the Wharton School of the University of Pennsylvania.
Laura Sampietro-Colom, MD, PhD
President from 2009-10 to 2010-11
Laura is a medical doctor (university of Barcelona) and earned her doctorate in medicine and surgery from the Autonomous University of Barcelona; she is an specialist in Public Health, and Master in Science of Public Health (Emory University, Atlanta, USA).
Laura has over 20 years of experience in evaluative research, specifically in Health Technology Assessment (HTA). She was one of the founders of the Catalan Agency for Health Technology Assessment, being now a research associate. She is a founding board member of the International Society for Health Technology Assessment (HTAi) and has been a Director of HTAi, including three years as the Secretary of the Executive Committee and two years as Vice-President.
Laura was partly responsible for the development of the first international project undertaken by the International Network of Agencies for Health Terchnology Assesment (INAHTA), and has collaborated actively in several other HTA European Projects, leading some areas of action. She has been temporary advisor of United Nations Agencies (WHO, PAHO, World Bank). She serves on the editorial board of the International Journal of technology Assessment in Health Care. She has been the Director of Projects, Evaluation and Information Systems at the Catalan Institute of Health, the main provider of public health care services in Catalonia; and the Head of the Strategic Planning Unit for health care organisation (Planning and Evaluation Directorate) of the Catalan Ministry of Health. Overall, Laura's work has focused on the evaluation of health care technologies, the identification, management and transference of information to improve the decision-making process, and on evidence-based planning healthcare services.
Currently, Dr Sampietro-Colom is the Deputy Director for Innovation at the “Hospital Clinic” in Barcelona, a leading Teaching Hospital in Spain.
Reiner Banken, MD, MSc
President from 2007-08 to 2008-09
Dr. Reiner Banken obtained his medical degree from Université de Montréal, where he also earned a master’s degree in Community Health. Consultant Researcher for AETMIS (the HTA agency for the province of Quebec) since 1998, he holds the position of Deputy Chief Executive Officer, Development and Partnerships since July 2005. He worked as an emergency physician for five years and as a specialist in public health for 12 years, including serving as Public Health Director for Québec’s Laurentian region.
Berit Mørland, DDS, PhD
President from 2005-06 to 2006-07
Dr. Mørland is Deputy Director General of the Norwegian Knowledge Centre for the Health Services. She was responsible for establishing the Norwegian Centre for Health Technology Assessment, which she has managed for the past 7 years, and was Director of the Norwegian Medical Research Council. Previously, she served as a clinician, taught and conducted research in universities, and worked in the pharmaceutical industry.
Her current interest in international collaboration has led to membership in committees in the EU, World Health Organization (WHO), North Atlantic Trade Organization (NATO), and the OECD. She has also been extensively involved in international HTA initiatives, formerly serving as Chair of INAHTA. Dr. Mørland is a Doctor of Dental Surgery and holds a PhD in Immunology
Chris Henshall, PhD
President from 2003-04 to 2004-05
Chris Henshall is Director of the Science and Engineering Base Group in the Office of Science and Technology in the Department of Trade and Industry in London, where he is responsible for around £3b (US $5b) per annum of government support for research and innovation. Before joining the Department of Trade and Industry, Dr. Henshall served as Deputy Director of Research and Development in the Department of Health. During his tenure there, he was closely involved in establishing the NHS HTA Programme, the National Institute for Clinical Excellence, and, with colleagues in other countries, INAHTA. Over the years, he has also been involved in various initiatives to promote and co-ordinate HTA across Europe.
Dr. Henshall is an Honorary Professor in the Department of Public Health and Policy in the London School of Hygiene and Tropical Medicine. Dr. Henshall has an MA and PhD from the University of Cambridge and an MA from the University of Nottingham.
Alicia Granados, MD, PhD
Chair of the Committee to Establish a New International Society for Health Technology Assessment
Up to January 2003, Dr. Granados was President and Chief Executive Officer of the Catalan Institute of Health. In this position, she managed Catalonia’s largest public health care provider, which comprises 11 large hospitals and more than 300 primary health-care centres and local consulting rooms. From 1994 to 1997, Dr. Granados was Director of the Catalan Agency for Health Technology Assessment, where she still remains a member of the Board. This agency generates health technology information to help inform decision-making in the Catalan Health Service, the Catalan Department of Health and Social Security, hospitals belonging to the Catalan Health Institute, and private health care organizations. Dr. Granados is also an Associate Professor in the Department of Medicine at the University of Barcelona.
From 2002 to 2003, she was President of the Board of Directors of the International Society of Technology Assessment in Health Care, following which she chaired the international committee assembled to create HTAi.
Dr. Granados completed both her medical degree and her Doctor of Philosophy in Medicine and Surgery at the University of Barcelona